Results 41 to 50 of about 100,614 (290)
Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine
Journal of Nucleic Acids, 2019 Gemcitabine (2′, 2′-difluorodeoxycytidine; dFdC) is a deoxycytidine analog and is used primarily against pancreatic cancer. The cytotoxicity of gemcitabine is due to the inhibition of DNA replication.
Joseph W. George +2 more
doaj +1 more source
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. [PDF]
PLoS ONE, 2012 Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance.
Foong Ying Wong +6 more
doaj +1 more source
Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
Frontiers in Oncology, 2021 BackgroundMetastasized soft-tissue sarcomas still pose a significant therapeutic challenge given the limited efficacy of currently available multimodal treatment strategies.
Dennis Christoph Harrer +9 more
doaj +1 more source
Advanced Science, EarlyView.Triple‐negative breast cancer exhibits variable sensitivity to PRMT5 inhibition. Basal interferon signaling is identified as a key biomarker of response. PARP inhibition with olaparib induces IFN signaling, sensitizing resistant TNBC cells to PRMT5 inhibitors.
Ziwen Zhang +9 more
wiley +1 more source
Advanced Science, EarlyView.Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance +17 more
wiley +1 more source
International Journal of Nanomedicine, 2012 Ji-Ho Lim1,*, Sung-Kyun You1,*, Jong-Suep Baek1, Chan-Ju Hwang1, Young-Guk Na1, Sang-Chul Shin2, Cheong-Weon Cho11College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Gungdong, Yuseonggu, Daejeon, South Korea,
Lim JH +6 more
doaj
Gut and Liver, 2021 Background/Aims: Although many studies have reported the promising effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC) to increase resectability, only a few studies have recommended the use of first-line chemotherapeutic ...
Yoo Jin Choi +15 more
doaj +1 more source
Advanced Science, EarlyView.PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li +17 more
wiley +1 more source
Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Neoplasia: An International Journal for Oncology Research, 2012 Checkpoint kinase 1 (Chk1) inhibition sensitizes pancreatic cancer cells and tumors to gemcitabine. We hypothesized that Chk1 inhibition would sensitize pancreatic cancer stem cells to gemcitabine.
Venkatasubbaiah A. Venkatesha +8 more
doaj +1 more source
Advanced Science, EarlyView.Histone 3 lysine18 lactylation (H3K18la) drives heterogeneous nuclear ribonucleoprotein C (HNRNPC) overexpression, activating autophagy to mediate gemcitabine resistance by stabilizing TNF receptor‐associated factor 6 (TRAF6) mRNA. Concurrently, HNRNPC stabilizes aldehyde dehydrogenase 1 family member A3 (ALDH1A3) mRNA, which enhances glycolysis and ...
Xi‐Tai Huang +9 more
wiley +1 more source